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Numb	was	originally	 identified	as	a	determinant	of	cell	 fate	 in	Drosophila,	and	more	re-
cently	as	a	tumor	suppressor	in	different	human	cancers.	Our	lab,	in	particular,	has	contrib-
uted	 to	 the	 characterization	 of	 Numb	 as	 a	 tumor	 suppressor.	 Indeed,	we	 showed	 that	

















ticular,	we	 characterized	Numb	 isoforms	expression	 in	BC	 cells	 and	 investigated	 the	 in-































particular,	 their	 involvement	 in	 tumorigenesis.	 In	 this	 introduction,	 I	 will	 provide	 an	
overview	 of	 the	 different	 Numb	 functions,	 starting	 from	 its	 discovery	 as	 a	 cell	 fate	
determinant	in	Drosophila	(Section	2.1)	and	ending	with	its	well-characterized	role	as	an	
endocytic	 adaptor	 protein	 and,	 more	 recently,	 as	 a	 tumor	 suppressor	 (section	 2.4).	 A	
particular	 focus	 will	 be	 placed	 on	 the	 latter	 point	 and	 the	 Numb-Mdm2-p53	 circuitry	
(section	 2.3.4),	 considering	 the	 key	 role	 that	 this	 circuitry	 plays	 in	 the	 cell	 and	 how	 its	
deregulation	has	a	profound	impact	on	tumorigenesis	(section	2.3.4.5).	Finally,	the	last	part	
of	 the	 introduction	will	 be	 focused	 on	 the	 consequences	 of	 loss	 of	 Numb	 in	 cancer	 to	
provide	 the	 rationale	 for	 possible	 therapeutic	 interventions	 in	 Numb-deficient	 tumors	
(section	2.3.4.6).	
	




to	 become	 “numb”,	 since	 it	 dramatically	 affects	 sensory	 neuron	 maturation	 during	









1).	 Alteration	 of	 this	 asymmetry,	 by	 either	 overexpression	 or	 depletion	 of	 Numb	 in	
Drosophila	results	in	cells	acquiring	the	same	cell	identity.	





The	 figure	 shows	 Numb	 asymmetric	 partition	 in	 Drosophila	 SOP	 cell	 (left)	 and	 central	
nervous	system	(CNS)	neuroblast	(right)	cell	division.	The	orientation	of	the	plane	of	division	
is	 indicated.	 Numb	 is	 depicted	 in	 green,	 as	 a	 crescent	 in	 the	 dividing	 SOP	 and	 in	 the	
neuroblast,	or	as	spheres	in	the	pIIb	cell	(one	of	the	daughter	cells	derived	from	SOP	division)	
and	in	the	ganglion	mother	cell	(GMC)	where	it	accumulates	after	the	first	asymmetric	cell	
division	 (ACD).	 For	 simplicity,	 only	 the	 first	 ACD	 in	 both	 lineages	 is	 depicted	 in	 detail.	













Concerning	 the	 first	point,	great	 interest	was	placed	 in	clarifying	how	Numb	partition	 is	
generated.	The	major	components	of	the	polarity	machinery	 involved	in	the	asymmetric	
partition	 of	 Numb	 at	 mitosis,	 during	 ACD,	 were	 intensively	 studied	 and	 are	 conserved	
between	flies	and	mammals.	The	process	seems	to	be	orchestrated	by	PAR	(par-titioning	–








intrinsic	 cell	 fate	 determinants,	 such	 as	 Mira,	 Prospero	 and	 Pon	 11,12,13,14	 (Fig.	 2B).	






A)	At	mitosis,	Aurora-A	 (AurA)–mediated	phosphorylation	of	Par-6	 leads	 to	activation	of	
aPKC	kinase	activity	on	Lethal	giant	 larvae	(Lgl).	Phosphorylated	Lgl	 is	excluded	from	the	




the	 plasma	membrane	 (green	 crescent)	 with	 other	 cell	 fate	 determinants.	 The	 ratio	 of	
apical/basal	 determinants	 specifies	 identity	 in	 each	 daughter	 cell	 (DNA,	 blue).	 Figure	
adapted	from	12.	
	

































wide	 interaction	 specificity	mediated	 by	 a	 flexible	 hydrophobic	 groove.	 This	 allows	 the	
backbone	structure	of	PTB	to	be	able	to	adopt	different	tertiary	conformations	adapted	by	
a	wide	range	of	intermolecular	binding	partners	18.	





















Human	Numb	 isoforms	1/2/3/4	 (p72,	p71,	p66,	p65	 respectively)	 structure	showing	 the	
main	 protein-protein	 interactor	 domains:	 phosphotyrosine	 binding	 domain	 (PTB,	 light	
orange),	the	proline-rich	region	(PRR,	light	blue),	and	the	DPF1,	DPF2,	and	NPF	motifs.	Exon	
numbering	 starts	 from	 the	 first	 Numb	 codifying	 exon.	 In	 dark	 orange,	 the	 alternatively	
spliced	exon	3	within	PTB	domain.	In	dark	blue,	the	alternatively	spliced	exon	9	within	PRR	






























these	 domains/motifs,	 Numb	 has	 been	 shown	 to	 interact	 with,	 and	 be	 involved	 in	 the	







of	 endocytosis	 is	 suggested	 by	 its	 temporally	 coordinated	 co-localization	 with	 AP2	 and	
Eps15	in	clathrin-coated	pits	and	early	endosomes	21,	and	by	its	localization	in	Arf6	GTPase-
containing	 vesicles,	 which	 are	 known	 to	 represent	 recycling	 endosomes	 24.	 These	
subcellular	localizations	have	suggested	a	role	of	Numb	as	a	cargo	selective	adaptor,	acting	
at	the	internalization	step	of	endocytosis	and	in	endosomal	trafficking	of	transmembrane	







of	 α-adaptin	 phenocopies	 loss	 of	 Numb,	 similarly	 affecting	 the	 bristle	 morphology	 in	
Drosophila	31.	Moreover,	in	the	SOP	system,	Numb	was	required	for	the	internalization	of	




























fate	 determination,	 homeostasis	 of	 the	 SC	 compartment,	 and	 regulation	 of	 the	
proliferative/differentiative	balance	during	development	and	in	adult	tissue	homeostasis	35.	
Notch	 signaling	 functions	 as	 an	 essential	 mechanism	 to	 direct	 cell	 fate	 decisions	 of	
neighboring	 cells	 through	 cell-cell	 physical	 interactions.	 Trans-interaction	 between	
receptors	and	ligands,	present	on	opposing	cells,	represent	activating	events	of	the	Notch	
signaling	pathway.	
Notch	 is	 an	 evolutionary	 conserved	 transmembrane	 receptor	 localized	 on	 the	 signal-
receiving	cell.	It	binds	directly	to	ligands	of	the	DSL	family	(Delta,	Serrate,	Lag-2	in	mouse;	
DLL1,	DLL2,	DLL3,	 Jagged	1/2	 in	human)	 located,	as	 integral	membrane	proteins,	on	the	























the	 endocytic	 function	 of	 Numb	 accounts	 for	 its	 biological	 antagonism	 of	 Notch	 (see	




interacts	 with	 both	 Notch	 and	 Numb.	 Numb,	 on	 the	 other	 hand,	 interacts	 with	 the	







Inhibition	of	Notch	signaling	 in	 the	SOP	system	results	 in	neuroblast	depletion,	while	 its	





Although	mammalian	 cells	 do	 not	 express	 Sanpodo,	 the	 general	 mechanism	 of	 Numb-
mediated	inhibition	of	Notch	is	conserved.	Mammalian	Notch	is	constitutively	internalized	
and	 either	 recycled	 back	 to	 the	 plasma	membrane	 or	 trafficked	 to	 the	 late	 endosomal	
compartment	for	degradation	40	(Fig.5).	It	has	been	demonstrated	that	changes	in	Numb	









negatively	 controlling	 recycling	 to	 the	 plasma	 membrane	 through	 AP1	 and,	 instead,	
increasing	Dll4	delivery	 to	 lysosomes	 for	degradation	 33.	 In	 this	way,	Numb	 limits	Notch	
signal	transmission	from	the	signal-sending	cell.	In	this	complex	scenario,	the	endocytic	role	
of	Numb	is	fundamental	to	remove	or	recycle	molecules	from	specific	plasma	membrane	






been	complemented	by	 several	 lines	of	evidence	 suggesting	an	additional	 tier	of	Numb	
regulation	on	Notch	signaling	via	 the	ubiquitin-proteasome	degradation	pathway.	Numb	
interacts	with	NICD	and	promotes	its	ubiquitination	driving	its	proteasomal	degradation,	
thus,	 resulting	 in	 attenuation	 of	 Notch	 signaling	 41	 (Fig.	 5).	 Numb	 recruits	 Itch	 (HECT	
domain-containing	 E3	 ligase),	 a	 component	 of	 the	 ubiquitination	machinery	 to	 the	 cell	
membrane-tethered	 Notch	 1	 receptor,	 thereby	 cooperatively	 enhancing	 Notch	





underlines	 that,	 at	 the	 molecular	 level,	 its	 upstream	 regulator	 Numb,	 has	 a	 tumor	
suppressor	role	in	different	cancer	contexts	(see	paragraph	2.4).		
In	conclusion,	tight	regulation	of	the	Numb-Notch	axis	is	essential	for	preventing	potential	













































functions	 as	 a	 signal-transmitting	 domain	 and	 a	 processing	 C-terminal	 "Hog”	 domain,	
involved	in	the	autocatalytic	intramolecular	cleavage	of	the	Hedgehog	ligand.	The	Hedge	
domain	 	 is	modified	 by	 the	 addition	of	 a	 cholesterol	moiety	 at	 its	 C-terminal	 52	 and	by	
palmitate	addition	to	the	N-terminal	by	an	acetyl	transferase	enzyme.	These	modifications	
allow	the	interaction	of	Hedge	with	lipoproteins.	The	modified	fully	active	“Hedge”	domain	













a	 transcriptional	 repressor	 50,53.	 The	 strength	 and	 duration	 of	 Hh	 signaling	 is	 strictly	
regulated	 by	 the	 ubiquitin-dependent	 proteolytic	 processing	 of	 Gli	 proteins.	 The	 Hh	
cascade	induces	different	set	of	target	genes	encoding	secreted	signaling	protein	involved	
in	 cell	 growth	 and	 division	 and	 many	 transcription	 factors	 that	 are	 essential	 for	
developmental	processes.	
The	role	of	Numb	in	this	context	is	to	suppress	Hh	signaling,	thereby	arresting	cell	growth	
and	 promoting	 cell	 differentiation.	 Numb	 interacts	 with	 the	 E3-ubiquitin	 ligase,	 Itch,	
promoting	 its	 ubiquitination	 of	 Gli1	 54,55	 (Fig.	 6A).	 This	 results	 in	 Gli1	 degradation	 and	
consequently	decreased	 transcriptional	activity	 leading	 to	downregulation	of	Gli1	 target	

















Sonic	hedgehog	 (SHH)	binds	 to	 the	receptor	Patched	 (PTC)	and	 inhibits	 its	 repression	of	
Smoothened	(SMO)(1).	Activated	SMO	translocates	to	the	nucleus	and	triggers	the	nuclear	
activity	of	the	GLI	transcription	factors.	GLI	proteins	regulate	Hh	target	gene	expression,	
promoting	 tumor	 proliferation	 and	 survival	 (2).	A)	Numb	 activates	 Itch	 ubiquitin-ligase	




The	 described	 mechanism	 highlighted	 a	 pro-differentiation,	 anti-proliferative	 effect	 of	
Numb	 in	 tumor	 cells	 due	 to	 suppression	 of	 functional	 Gli	 activity	 (Fig.	 6B).	 Aberrant	
activation	 of	 the	 Hh	 signaling	 can	 enhance	 survival	 and	 proliferation	 of	 cells,	 inducing	
tumorigenesis	 and	metastasis	 formation	 56–60.	 Aberrant	 activation	 of	 the	Hh	 pathway	 is	




of	 the	 Numb-Hh	 axis	 could	 be	 relevant	 to	 tumorigenesis.	 Moreover,	 since	 a	 signaling	
crosstalk	between	Notch	and	Hh	is	involved	in	normal	developmental	processes,	as	well	as	
in	tumorigenesis,	an	 interesting	scenario	emerges	 in	which	Numb	might	act	as	a	master	



















encountered	 by	 cells	 66.	 p53	 acts	 like	 a	 cellular	 stress	 sensor	 that	 can	 be	 activated	 in	
response	 to	 different	 stimuli,	 such	 as	 DNA	 damage,	 hyper-proliferative	 signals	 as	
consequence	of	oncogene	activation,	hypoxia,	oxidative	 stress,	 ribonucleotide	depletion	












G1	 block)	 and	 DNA	 repair.	 In	 contrast,	 high	 levels	 of	 sustained	 stress,	 accompanied	 by	
irreparable	 damage,	 induce	 the	 killer	 functions	 of	 p53	 that	 consist	 in	 p53-mediated	
activation	of	cell	death	or	senescence	68	(Fig.	7).	Both	these	response	modes	help	to	prevent	


































































v)	C-terminal	basic	 region	 spanning	amino	acids	356-393,	which,	 as	 suggested	 from	 the	
name,	 is	 rich	 in	 basic	 residues.	 Its	 conformational	 flexibility	 allows	 the	 region	 to	 adopt	
alternative	 conformations	 and	 provides	 binding	 specificity.	Moreover,	 it	 is	 subjected	 to	




























precise	 site	 and	 on	 the	 modifying	 kinase	 (ATM,	 cAbl)	 or	 acetylase	 (CBP/p300)	 (see	
paragraph	2.4.4.3)	66.	
In	the	same	way,	p53	activation	is	regulated	by	an	array	of	PTMs.	Regulatory	redundancy	
among	 p53	 PTMs	might	 ensure	 that	 p53	 is	 regulated	 appropriately	 in	 a	 tissue-specific	
manner	 in	 response	 to	different	 stimuli	and	different	 strength	of	 signals	 78.	Genetic	and	
biochemical	 studies	 emphasize	 the	 notion	 that	 p53	 stabilization	 in	 vivo	 requires	 a	
sophisticated	regulatory	network.	Different	kinases	(ATM,	ATR,	DNAPK,	CHK1,	CHK2)	can	
affect	the	p53-Mdm2	interaction	by	phosphorylating	N-terminal	TAD	of	p53	and	stabilizing	
the	 protein	 in	 response	 to	 various	 stress	 signals.	 Recent	 work	 has	 demonstrated	 that	
acetylation	of	p53	C-terminal	lysine	residues	by	CBP/p300	is	required	for	p53	stabilization	







genes.	 p53	 binding	 to	 DNA	 occurs	 through	 the	 central	 conserved	 DBD	 that	 provides	
sequence	specificity.	The	p53	C-terminal	 region	recognizes	 instead	structural	 features	of	
target	 DNA	 and	 folds	 back	 acting	 as	 a	 negative	 modulator	 of	 DNA	 binding	 domain.	
Additional	 p53	 PTMs	 interfere	 with	 this	 folding	 and,	 at	 the	 same	 time,	 regulate	 the	











different	 regions	 in	 the	 protein	 might	 be	 important	 for	 selection	 of	 target	 genes	 to	
transactivate.	Also	methylation,	sumoylation,	and	neddylation	also	occur	at	specific	sites	in	



















activation	of	 target	genes	both	by	preventing	p53	 interaction	with	coactivators	 (it	 com-














































Recent	evidence	highlights	 a	previously	unexpected	 role	of	 endogenous	Mdm2	 in	mito-
chondria	(mtMdm2)	that	is	independent	of	p53.	It	was	shown	that	Mdm2	is	actively	im-
















Indeed,	 amplification	 of	 the	MDM2	 gene	 is	 a	 common	 event	 occurring	 in	 over	 17%	 of	
tumors	 90.	 This	 event	 accounts	 for	 Mdm2	 overexpression	 and	 contributes	 to	 p53	











































































and	 progression	 of	 cancer.	 Tumors	 with	 p53	 dysfunction	 are	 characterized	 by	 genomic	





number	of	cases,	p53	dysfunction	 is	due	 to	mutations	of	 the	p53	 gene	or	 in	genes	 that	




p53-responsive	 element	 on	 promoters	 of	 target	 genes.	 The	 functional	 impact	 of	 these	
mutations	is	dysregulated	p53	transactivation	activity.	Transcriptional	activity	requires	the	
formation	of	p53	tetramers	(dimers	of	dimers).	Incorporation	of	a	mutant	p53	monomer,	
















progression.	The	emerging	 theme	 is	 that	p53	has	a	pivotal	 role	 in	maintaining	organism	
















ii) inhibition	of	Mdm2	or	Mdm2-p53	 interaction	using	small	molecule	 inhibitors	 114,	
(see	paragraph	2.3.4.6),	such	as	Nutlin		115.	
iii) restoration	of	 the	p53	WT	conformation	 in	mutated	cases	 116.	Mutant	p53	often	
accumulates	in	cancer	cells	and	therefore	represents	a	tumor-specific	biomarker	117,118.	In	




These	 compounds	 include	 PRIMA-1,	 MIRA-3,	 STIMA-1,	 PhiKan083,	 ellipticine,	 P53R,	
NSC319726,	CP31398	[reviewed	in	106].	
iv) targeting	mutant	p53	to	degradation	119.	An	alternative	strategy	in	tumors	addicted	









Considering	 the	above,	 it	 is	clear	 that	 the	evaluation	of	p53	status	 in	 tumors	 is	of	great	
importance	in	deciding	the	appropriate	treatment	strategy.	Many	p53	mutations	 lead	to	
abnormal	 p53	 nuclear	 accumulation118.	Mutant	 p53	 protein	 probably	 accumulates	 as	 a	
result	 of	 compromised	 p53-mediated	 transcription	 of	 its	modulator	Mdm2.	As	 a	 result,	
mutant	p53	has	a	longer	half-life	compared	to	the	relatively	unstable	WT	protein.	Based	on	




cohorts	 demonstrated	 that	 p53	 accumulation	 is	 an	 independent	 parameter	 of	 poor	
 46 
prognosis	 124.	 It	has	emerged,	however,	 that	also	undetectable	p53	nuclear	staining	 is	a	
likely	 indicator	 of	 null-mutations	 in	 the	 p53	 gene	 and	 poor	 prognosis	 118.	 p53	 gene	
sequencing	clearly	remains	the	most	reliable	technique	to	assess	p53	mutational	status	in	




















2.3.4.6 TARGETING	 OF	 THE	 p53-MDM2	 PATHWAY	 FOR	
CANCER	THERAPY		
The	MDM2-p53	pathway	has	been	widely	studied	and	presents	an	attractive	target	for	can-






























































Mdm2	 interaction	 from	our	 lab	has	 further	 illuminated	 the	mechanism	of	 the	action	of	






dynamic	 loop	 able	 to	 adopt	 at	 least	 three	 different	 conformations.	 This	 flexible	 loop	 is	
enriched	in	aromatic	and	positively	charged	amino	acids	136.	Nuclear	magnetic	resonance	
(NMR)	 chemical	 shifts	 and	 mutational	 analysis	 suggested	 that	 Numb	 PTBi	 residues	






phosphopeptide	 (violet).	 GPpY	 is	 a	 phosphopeptide	 that	 derives	 from	 a	 canonical	 PTB-
binding	 protein.	 The	 11	 aa	 exon3-encoded	 sequence	 is	 depicted	 in	 red.	 B)	 Schematic	
representation	 indicating	 that	 the	 PTBi:Mdm2	 interaction	 interface	 represents	 a	 fuzzy	
complex,	where	two	intrinsically	disordered	regions	in	both	binding	partners	interact	and	
retain	dynamic	and	intrinsic	disorder	in	the	complex.	The	Numb-Mdm2	interaction	is	based	






different	PTMs,	 in	particular,	 phosphorylation	of	 different	 residues,	which	 contribute	 to	
maintain	 the	 interaction	with	p53	under	 ‘unstressed’	 conditions	when	 the	cell	needs	 to	
maintain	 low	 levels	 of	 p53.	 Phosphomimic	 mutants	 of	 Mdm2	 that	 mimic	 the	
phosphorylation	occurring	 in	vivo,	were	able	to	increase	the	binding	to	Numb,	indicating	
that	 probably	 also	 some	 PTMs	 might	 contribute	 to	 the	 Numb-Mdm2	 interaction.	 The	























To	 acquire	migratory	 traits,	 cells	 need	 to	 undergo	 epithelial-to-mesenchymal	 transition	
(EMT).	EMT	is	a	process	in	which	epithelial	cells	acquire	pro-metastatic	migratory	traits	by	
expressing	mesenchymal	markers	while	losing	their	cell-cell	contacts	and	polarity.	Numb	





clathrin-coated	 pits	 at	 the	 substratum-facing	 cell	 surface.	 These	 interactions	 allow	 the	
control	of	 integrin	endocytic	 trafficking,	 from	their	 internalization	 to	 their	 route	back	 to	
plasma	membrane	to	make	new	adhesion	sites	at	the	leading	front	28.	
Numb	is	also	involved	in	the	EMT	process	by	regulating	cell	polarity	in	epithelial	cells.	Cell	












In	 the	context	of	 cancer,	 the	downmodulation	of	Numb	can	causally	drive	an	enhanced	
tumor	invasion	by	prompting	the	EMT	phenotype	142,143	.	Taken	together,	these	data	suggest	
a	role	of	Numb	in	driving	all	the	steps	of	the	EMT	process,	from	loss	of	cellular	polarity	and	
cell-cell	 contacts	 (dynamic	 remodulation	 of	 AJs	 and	 TJs),	 actin	 remodeling	 and	 cell-to-
extracellular	matrix	dynamics	for	cell	migration. 
	
2.3.6 INCREASING	 THE	 COMPLEXITY:	 THE	 ROLE	 OF	
NUMB	ISOFORMS		
Recent	 evidence	has	 highlighted	 another	 level	 of	 complexity	 in	 the	 regulation	of	Numb	
biochemical	 functions	 concerning	 the	 differential	 role	 of	 Numb	 isoforms.	 As	 previously	













developing	 pancreas	 and	 retina,	 where	 isoforms	 1	 and	 3	 are	 expressed	 in	 early	




an	 increase	 in	 exon	 9-lacking	 isoforms	 2	 and	 4	 144.	 The	 mechanism	 underlying	 the	














146.	 The	 production	 and	 abundance	 of	 splice	 variants,	which	 exert	 sometimes	 opposing	
functions,	 is	 dynamically	 regulated	 in	 a	 temporal	 and	 spatial	 manner	 147.	 Notably,	
deregulation	of	the	alternative	splicing	of	Numb,	 leading	to	alterations	 in	Numb	isoform	
expression,	has	been	observed	in	different	cancers,	suggesting	a	role	of	aberrant	alternative	
splicing	 in	the	tumorigenic	processes.	 Indeed,	 increased	expression	of	exon	9-containing	

























Another	 strong	 indication	of	differential	 roles	of	exon	3-containing	vs.	 -lacking	 isoforms	


























can	be	appreciated	considering	that	 loss	of	Numb	protein	 is	detected	 in	around	30%	of	
breast	and	lung	tumors	(Numb-deficient)	and	it	is	correlated	with	poor	prognosis	(higher	























proliferative/differentiative	 balance.	 Numb	 expression	 levels	 inversely	 correlate	 with	





damage	63.	This	 is	 linked	to	 increased	resistance	of	Numb-deficient	tumors	to	genotoxic	















On	 the	 left,	 Numb	 regulation	 on	 Integrin,	 adherens	 junction	 (AJs)	 dynamics	 and	 on	






2.4.1 NUMB	 INVOLVEMENT	 IN	 CANCER:	 THE	 ROLE	 IN	





undergoes	 mitotic	 expansion	 and	 progressive	 lineage-specific	 differentiation.	 ACD	 thus	
ensures	the	preservation	of	the	SC	pool	while	allowing	the	proliferation	of	differentiated	
cells	 163.	 The	 correct	 execution	of	ACD	 likely	 represents	 a	mechanism	 to	prevent	 tumor	
development.	 This	 latter	 point	 is	 supported	 by	 evidence	 showing	 that	 uncontrolled	
symmetric	 division	 of	 SCs	 is	 associated	 with	 tumorigenesis	 70.	 The	 symmetric	 mode	 of	

















In	 the	 progenitor	 daughter	 cell,	 Numb	 progressively	 re-accumulates	 and	 appears	 to	 be	








Fig.	19	Role	of	Numb	 in	 the	maintenance	of	 the	 stem	and	progenitor	 cell	pools	 in	 the	
mammary	epithelium.		
Left,	during	normal	mammary	stem	cell	mitosis,	ACD	prevail,	maintaining	the	stem	cell	pool	





Right,	when	Numb	 function	 is	 lost,	p53	activity	 is	decreased	 favouring	expansion	of	 the	




expression	 and	 consequently	 of	 p53	 activity	 at	 the	 level	 of	 the	 SC	 compartment	 in	 the	
mammary	gland	results	in	a	skewing	in	the	mode	division	towards	a	symmetric	mode	and	







tumorigenesis.	 The	 selective	 ablation	of	Numb	 in	 the	mouse	mammary	 gland	 results	 in	
morphological	 alterations	 and	 development	 of	 preneoplastic	 lesions.	 Thus,	 Numb	
regulation	of	p53	stability	 represents	physiologically	a	 tumor	suppressor	barrier	 that,	by	
maintaining	SC	homeostasis,	safeguards	against	their	uncontrolled	expansion.		
Notably,	the	restoration	of	the	Numb/p53	circuitry	in	Numb-deficient	tumors	can	override	




































































































antibiotics	 (Sigma). BT-474	cells	were	cultured	 in	DMEM,	10%	FBS	North	American	fetal	
bovine	serum	(FBS	NA),	2	mM	L-	glutamine	and	100	µg/mL	penicillin	and	streptomycin	an-
tibiotics.	MCF-10A	cells	were	maintained	in	a	1:1	mixture	of	DMEM	and	Ham	F12	medium	
(Invitrogen)	 supplemented	 with	 5%	 horse	 serum	 (Invitrogen),	 10	 µg/ml	 human	 insulin	
(Boehringer-Mannhaim),	 0.5	 µg/ml	 hydrocortisone	 (Sigma),	 100	 ng/ml	 cholera	 toxin	
(Sigma),	100	µg/mL	penicillin	and	streptomycin	antibiotics	(Sigma)	and	2	mM	L-glutamine.	












cells	 were	 collected	 in	Mammary	 Epithelial	 Basal	Medium	 (MEBM).	 Serum-free	MEBM	
(Clonetics)	was	supplemented	with	5	µg/ml	insulin,	0.5	µg/ml	hydrocortisone,	1	U/ml	hep-
arin	(Wockhardt),	2	mM	glutamine	and	100	µg/mL	penicillin	and	streptomycin	antibiotics.	

























Lipofectamine	RNAiMAX	 in	 500	μl	OPTIMEM.	The	mixture	was	 incubated	 for	 20	min	 at	
room	temperature	(RT).	Cells	were	plated	in	a	total	volume	of	2	ml	of	complete	medium	




































































































































4.3.3.3 IHC	 CHARACTERIZATION	 OF	 p53	 MUTATIONAL	
STATUS	ON	BC	SAMPLES	
p53	functionality	is	often	compromised	in	cancer,	by	direct	mutations	of	the	p53	gene	or	





cases	 collected	 at	 the	 European	 Institute	 of	 Oncology	 (IEO,	 Milan)	 via	 standardized	
operative	procedures,	from	BC	patients	who	underwent	surgery	between	years	1997	and	






































































Hs01105433_m1	 for	 ‘NUMB	 TOT’	 (NUMB	 isoform-1:	 NM_001005743.1,	 -2:	
NM_001005744.1,	 -3:	NM_003744.5	and	 -4:	NM_001005745.1),	Hs01105434	 for	NUMB	
1/3,	 Hs02800695_m1	 (HPRT1),	 Hs03929097_g1	 (GAPDH),	 Hs99999908_m1	 (GUSB),	
Hs01060665_g1	 (ACTB),	 Hs00963534_m1	 (ALAS1)	 and	 Hs00427621_m1	 (TBP)	 all	 pur-
chased	from	Thermo	Fisher	Scientific.	
The	custom	TaqMan	gene	expression	assays	to	detect	NUMB	1/2	(forw.GATGAATCAAGAG-
GAATGCACATC;	 rev.	 TGAAGAACTTCCTTTCAGCTTTCAA;	 probe:	 TGAAGATGCTGTAAAAAG)	
and	 NUMB	 2/4	 forw.	 TGGCACCACAATCTCCTACCT;	 rev.	 AGGCAGCACCAGAAGATTGAC;	
probe:	CCAAGGGACCGAGTGG)	were	designed	using	the	Primer	Express	Software	V3.0	and	
purchased	from	Thermo	Fisher	Scientific.	The	custom	TaqMan	assay	to	detect	NUMB	3/4	

















































of	one	of	 the	samples.	The	 following	assays	were	used	 (see	Fig.	21):	A	 (Hs01105431),	B	
(Hs01105433_m1),C	 (forward	 primer:	 GCGGTCAAAGGAGCAAAACA;	 reverse	 primer:	
GGGACCTTTGGGATTAGTGAAAA;	probe:	ACTTTGTCTCCTGATTAGTAC	).	
	












temperatures	 (Tm).	 Initial	 denaturation	95°C	2	min,	35	 cycles	 (each	 cycle:	denaturation	
95°C	1	min,	annealing	62°C	1	min,	extension	72°C	3	min).	After	amplification,	15	µl	of	PCR	
























5.1 EVALUATION	 OF	 THE	 EXPRESSION	 OF	 NUMB	
ISOFORMS	IN	BREAST	CELL	LINES	
	
The	 aim	 of	 this	 thesis	was	 to	 elucidate	 the	 role	 of	 the	 different	 Numb	 isoforms	 in	 the	
regulation	of	p53	and	their	relevance	and	contribution	to	breast	carcinogenesis.	We	used	







































The	 PCR	 products	 were	 analyzed	 on	 an	 agarose	 gel	 to	 discriminate	 the	 length	 of	 the	
amplified	DNA	 (Fig.	 22B).	 In	all	 the	 samples,	we	observed	 two	main	bands	>1000	bp	 in	
length	likely	corresponding	to	Numb	isoforms	1	to	4.	Considering	the	very	similar	sizes	of	
isoforms	1	and	3	and	of	isoforms	2	and	4	it	was	not	possible	to	distinguish	between	these	
pairs.	 Indeed,	 in	 MCF-10A	 cells,	 in	 which	 we	 have	 confirmed	 at	 the	 protein	 level	 the	
expression	of	isoforms	1	to	4	(see	Fig.	25C),	we	only	observed	two	main	bands	in	the	PCR	
reaction.	












A)	 Schematic	 representation	 of	 exon	 composition	 of	 all	 nine	 Numb	 isoforms,	 with	 the	













Numb	physiologically	 binds	 to	 and	 inhibits	Mdm2,	 thereby,	 preventing	Mdm2-mediated	
ubiquitination	 of	 p53	 and	 stabilizing	 the	 p53	 tumor	 suppressor	 protein	 63.	 Recent	









basal	 protein	 expression	 and/or	 the	 poor	 affinity	 of	 commercially	 available	 antibodies,	
which	often	hinder	co-immunoprecipitation	experiments,	we	exogenously	expressed	FLAG-
tagged	Numb	isoforms	and	WT	Mdm2	in	the	human	embryonic	kidney	cell	line,	HEK-293,	
which	 is	 known	 for	 its	 high	 transfection	 efficiency.	 We	 performed	 an	 anti-FLAG	
immunoprecipitation	 experiment	 and	 analyzed	 the	 immunoprecipitated	 proteins	 by	
immunoblotting	 (IB)	 with	 anti-FLAG	 and	 anti-Mdm2	 antibodies.	 Results	 revealed	 that	
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and	 with	 WT	 Mdm2	 were	 immunoprecipitated	 (IP)	 with	 the	 anti-FLAG	 antibody	 and	





In	 the	 IB,	 we	 observed	 a	 doublet	 for	Mdm2	with	 a	MW	 of	 ~90	 kDa,	 compared	with	 a	
theoretical	MW	of	55	kDa.	While	the	slower	migration	of	Mdm2	in	polyacrylamide	gels	has	
been	already	described,	we	do	not	know	exactly	the	nature	of	the	doublet,	although	it	is	
probably	 due	 to	 a	 post-translational	 modification	 (PTM)	 of	 the	 protein.	 However,	 we	
demonstrated	that	the	Mdm2	antibody	used	is	specific	for	the	protein,	by	interfering	Mdm2	






Lysate	 of	 Hek-293	 cells	 transfected	 with	 Mdm2	 siRNA	 oligo	 (10nM),	 Ctr	 siRNA	 or	 not	










effects	 of	Numb	 silencing	 on	 p53	 protein	 levels	 in	 the	MCF-10A	 cell	 line,	 by	 selectively	






























































































and	 culturing	 in	 fresh	medium	 for	 a	 further	 24	 h	 to	 allow	DNA	 repair.	 Cells	were	 then	
analyzed	before	(Cisplatin)	and	after	(Cisplatin	+	24	h	release)	washout	by	IF	using	an	anti-
phosphorylated	 γ-H2AX	 antibody.	 For	 each	 condition,	 ten	 random	 fields	 were	 analyzed	
(from	two	independent	experiments),	counting	the	number	of	γH2AX	foci/cell.	In	each	field,	
we	 calculated	 the	percentage	of	 cells	 displaying	0-1,	 2-10,	 >10	 γH2AX	 foci/nucleus.	 The	
graph	reports	the	mean	+	sd	of	these	percentages	calculated	for	each	condition.	*=	P-value	
£0.01	compared	with	Ctr-siRNA	in	each	group.	B)	Representative	panels	showing	IF	staining	










primary	 BCs	 deficient	 in	 Numb	 1/2	 expression	 should	 display	 increased	 resistance	 to	




Cells	were	 treated	with	 cisplatin	 (Fig.	 29A)	or	 cisplatin	plus	Nutlin-3a	 (Fig.	 29B)	 for	 9	h,	
released	 for	 72	 h	 in	 fresh	medium	 and	 then	 analyzed	 for	 their	 viability	 (Fig.	 29A-B).	 A	
significant	 inverse	 correlation	between	 the	mRNA	 levels	 of	Numb	 isoforms	1/2	 and	 cell	
viability	was	observed,	while	no	evident	correlation	could	be	evidenced	with	 the	mRNA	





the	effect	 is	mediated	by	p53.	 To	exclude	a	 toxic	effect	of	Nutlin-3a,	we	also	 treated	 in	
























isoforms	 3/4	 (middle)	 or	 total	 Numb	 (bottom,	 Numb-TOT),	 determined	 in	 Fig.	 28.	 R=	
Pearson	 correlation	 coefficient	 and	 relative	p-value	 (P)	 determined	using	 the	 two	 tailed	
Student’s	t	test	are	shown.	D)	Viability	of	primary	BC	cells,	as	a	function	of	Numb	1/2	mRNA	
levels,	 after	 treatment	 with	 cisplatin	 (Cispl)	 or	 cisplatin+Nultin-3a	 (Cispl+Nutl).	 The	 13	
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primary	 BC	 cells	 analyzed	 in	 Fig.	 28	were	 grouped	 according	 to	 the	 level	 of	 Numb	 1/2	
expression	(low,	intermediate	or	high)	defined	as	tertiles	of	expression.	The	data	are	shown	
as	the	average	value	within	these	three	groups	+	sd.	P-values	were	determined	using	two	








We	 reasoned	 that	 low	 mRNA	 levels	 of	 Numb	 isoforms	 1	 and	 2	 in	 BCs,	 in	 addition	 to	




of	 890	 formalin-fixed	 paraffin-embedded	 (FFPE)	 patients	 to	 investigate	 the	 correlation	








































RT-qPCR	 procedure,	 we	 compared	 this	 method	 with	 digital	 PCR.	 This	 latter	 approach	
allowed	 us	 to	 quantify	 the	 amplified	 copies	 in	 absence	 of	 a	 pre-amplification	 step.	We	
extracted	RNA	from	five	FFPE	samples	prepared	from	breast	tumors	and	retrotranscribed	
to	cDNA.	The	RT-qPCR	analysis	(after	cDNA	pre-amplification)	and	the	digital	PCR	analysis	
were	 performed	 in	 parallel.	 Comparing	 these	 two	 techniques,	 the	 trend	 in	 the	 relative	
















Having	verified	 the	 technical	 set-up	of	 the	assay,	we	proceeded	with	 the	analysis	of	 the	
case-cohort	of	890	BC	patients.	RNA	extracted	from	each	sample	was	retrotranscribed,	pre-
amplified	and	analyzed	for	the	expression	of	total	Numb,	Numb	isoforms	1/2	vs.	3/4,	and	























calculated	 using	 univariate	 Cox	 proportional	 hazards	 regression	 model.	 Low,	 lowest	
expression	 quintile:	 High,	 remaining	 four	 quintiles.	 HR=hazard	 ratio;	 P=	 p-value.	 In	 the	
entire	case-cohort	(N=890),	multivariable	analyses	were	adjusted	for	Grade,	Ki-67,	tumor	















1/2	 status	 emerged	 as	 an	 independent	 predictor	 of	 risk	 of	 disease	 recurrence,	 in	
multivariable	analysis,	both	in	the	entire	luminal	subcohort	(HR=1.54	,	p=0.03)	and	in	the	
p53-WT	luminal-subcohort	(HR=1.59	,	p=0.05).	These	findings	are	in	accordance	with	our	
results	 indicating	 an	 increased	 resistance	 to	 genotoxic	 treatments	 in	 the	 primary	 BCs	
















Univariate	 and	multivariable	 analyses	 are	 calculated	using	 the	Cox	proportional	 hazards	
regression	model.	In	the	entire	case-cohort	(N=890),	multivariable	analyses	were	adjusted	
for	Grade,	Ki-67,	tumor	size,	number	of	positive	lymph	nodes,	age	at	surgery,	ERBB2	status	















1/3	and	2/4	are	 indicative	of	poor	prognosis	 in	BCs,	whereas	no	 correlation	 came	 from	
Numb	3/4	status.	The	result	was	further	evidenced	in	the	p53-WT	patients,	indicating	an	


































or	 counteract	 cancer	 cell	 development.	 Thus,	 deregulation	 of	 alternative	 splicing	 could	














splicing	 events,	 the	Numb	exon	3	 region	 is	 included	 in	 two	out	 of	 four	Numb	 isoforms	
(Numb	1/2)	suggesting	a	Numb	isoform-specific	role	in	Mdm2-p53	circuitry	regulation.		






















mimicking	 the	 Numb	 exon	 3-encoded	 surface	 on	 Mdm2	 could	 rescue	 p53	 function	 in	
Numb-deficient	tumors.	
	






specifically	 in	p53-WT	BCs.	These	 results	 further	 support	 the	 idea	 that	 the	 relevance	of	






















in	 Numb-deficient	 BCs	 has	 been	 represented	 by	 post-translational	 events	 causing	 en-
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